NRXP Key Statistics, Chart & Performance
The current stock price of NRXP is 2.71 USD. In the past month the price increased by 19.38%. In the past year, price increased by 0.74%.
NRXP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.87 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.94 | 498.60B | ||
| MRK | MERCK & CO. INC. | 11.95 | 261.26B | ||
| PFE | PFIZER INC | 7.78 | 141.57B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.22 | 109.81B | ||
| ZTS | ZOETIS INC | 19.85 | 55.45B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 22.30B | ||
| VTRS | VIATRIS INC | 5.34 | 14.34B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.57 | 11.24B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.21B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.58B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.42B |
Related stock screener links
About NRXP
Company Profile
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is headquartered in Wilmington, Delaware. The company went IPO on 2017-11-20. The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.
Company Info
NRX THERAPEUTICS INC
1201 Orange Street, Suite 600
Wilmington DELAWARE US
CEO: Richard Ackerman
Employees: 2
Phone: 14842546134
NRX THERAPEUTICS INC / NRXP FAQ
What does NRX THERAPEUTICS INC do?
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is headquartered in Wilmington, Delaware. The company went IPO on 2017-11-20. The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.
Can you provide the latest stock price for NRX THERAPEUTICS INC?
The current stock price of NRXP is 2.71 USD. The price increased by 3.04% in the last trading session.
Does NRXP stock pay dividends?
NRXP does not pay a dividend.
What is the ChartMill technical and fundamental rating of NRXP stock?
NRXP has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists NRXP stock?
NRXP stock is listed on the Nasdaq exchange.
Can you provide the ownership details for NRXP stock?
You can find the ownership structure of NRX THERAPEUTICS INC (NRXP) on the Ownership tab.
NRXP Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to NRXP. When comparing the yearly performance of all stocks, NRXP is a bad performer in the overall market: 73.44% of all stocks are doing better.
NRXP Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NRXP. NRXP has a bad profitability rating. Also its financial health evaluation is rather negative.
NRXP Financial Highlights
Over the last trailing twelve months NRXP reported a non-GAAP Earnings per Share(EPS) of -1.79. The EPS increased by 12.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -253.81% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NRXP Forecast & Estimates
10 analysts have analysed NRXP and the average price target is 37.23 USD. This implies a price increase of 1273.8% is expected in the next year compared to the current price of 2.71.